m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03804)
Name
PEDF gene therapy
Synonyms
AdPEDF; AdGVPEDF.11D; PEDF gene therapy (ophthalmic); PEDF gene therapy (ophthalmic), GenVec; Pigment epithelium-derived factor gene therapy, GenVec
    Click to Show/Hide
Status
Phase 1
TTD Drug ID
D0PF8B
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Pigment epithelium-derived factor (SERPINF1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Pigment epithelium-derived factor (SERPINF1) is a therapeutic target for PEDF gene therapy. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PEDF gene therapy through regulating the expression of Pigment epithelium-derived factor (SERPINF1). [1], [2]
References
Ref 1 The m6A Methyltransferase METTL3 Is Functionally Implicated in DLBCL Development by Regulating m6A Modification in PEDF. Front Genet. 2020 Aug 27;11:955. doi: 10.3389/fgene.2020.00955. eCollection 2020.
Ref 2 Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35. doi: 10.1517/14728214.10.1.119.